Serelaxin - Novartis

Drug Profile

Serelaxin - Novartis

Alternative Names: ConXn; Reasanz; Recombinant human relaxin H2; Recombinant relaxin; Relaxin; Relaxin H2; rhRlx; RLX-030; RLX-030A; SUN-Y8002

Latest Information Update: 20 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Howard Florey Institute
  • Developer Corthera; Genentech; Novartis
  • Class Heart failure therapies; Peptide hormones
  • Mechanism of Action Peptide hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse scleroderma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute heart failure
  • Discontinued Chronic heart failure; Coronary artery disease; Diffuse scleroderma; Female infertility; Fibrosis; Labour disorders; Labour induction; Liver cirrhosis; Peripheral arterial disorders; Portal hypertension; Preeclampsia; Pulmonary fibrosis; Pulmonary hypertension

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 18 Oct 2017 University of Edinburgh initiates the phase II STOPP trial in Cirrhosis and Portal hypertension in United Kingdom (IV) (NCT02669875)
  • 12 Jul 2017 Novartis terminates the phase III RELAX AHF-Pan EU trial for Acute heart failure (Adjunctive treatment) based on results from pivotal adult AHF study CRLX030A2301 in Austria, Belgium, Denmark, Hungary, Italy, Bulgaria, Croatia, Czech Republic, Estonia, Finland, France, Germany, Greece, Iceland, Latvia, Lithuania, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland and the UK (IV) (NCT02064868)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top